US stock · Healthcare sector · Drug Manufacturers—General
Company Logo

Amgen Inc.

AMGNNASDAQ

226.97

USD
-0.78
(-0.34%)
Market Closed
19.30P/E
12Forward P/E
0.96P/E to S&P500
121.413BMarket CAP
3.25%Div Yield
Upcoming Earnings
31 Oct-4 Nov
Shares Short
8/31/22
16.52M
Short % of Float
3.09%
Short % of Shares Outs.
3.09%
% Held by Insiders
0.22%
% Held by Institutions
80.12%
Beta
0.56
PEG Ratio
1.61
52w. high/low
258.45/198.64
Avg. Daily Volume
2.64M
Return %
Stock
S&P 500
1 year
5.88
(16.94)
3 years
16.58
24.12
5 years
21.72
47.77
Scale: |
High
Low
76.95
46.21
66.51
39.16
64.76
44.96
61.26
50.26
65.00
47.66
90.81
63.30
119.70
81.56
173.14
108.20
181.81
130.09
176.85
133.64
191.10
147.12
210.19
163.31
244.99
166.30
264.97
177.05
276.69
198.64
258.45
214.39
Currency: USD
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Revenue per share
12.13
13.22
14.02
14.41
15.68
17.22
22.28
24.80
26.43
28.58
30.74
31.26
35.93
38.61
43.39
44.33
47.71
Earnings per share
2.51
2.83
3.92
4.53
4.82
4.07
5.61
6.75
6.80
9.15
10.32
2.71
12.70
12.96
12.40
10.06
11.85
FCF per share
3.55
3.70
4.97
5.71
5.42
5.03
6.70
7.43
9.95
11.12
12.72
14.38
15.97
14.10
16.88
14.30
11.54
Dividends per share
- -
- -
- -
- -
- -
0.55
1.44
1.88
2.44
3.16
4.01
4.60
5.31
5.80
6.41
6.85
7.43
CAPEX per share
1.04
1.13
0.63
0.52
0.60
0.63
0.89
0.92
1.32
0.86
1.12
0.91
1.12
1.02
1.04
1.50
1.40
Book Value per sh.
16.13
16.00
19.05
22.31
24.94
21.03
24.59
29.34
33.96
37.05
39.94
34.53
18.91
15.99
16.06
11.43
8.25
Comm.Shares outs.
1,176
1,117
1,070
1,016
960
905
775
753
759
758
748
731
661
605
586
586
553
Avg. annual P/E ratio
28.3
20.5
13.0
12.1
11.5
13.7
13.6
15.4
19.4
17.2
15.0
62.9
14.8
15.1
18.5
23.1
19.3
P/E to S&P500
1.6
1.2
0.6
0.2
0.6
0.8
0.9
0.9
1.1
0.9
0.7
2.7
0.6
0.6
0.5
0.8
1.0
Avg. annual div. yield
- -
- -
- -
- -
- -
1.0%
1.9%
1.8%
1.9%
2.0%
2.6%
2.7%
2.8%
3.0%
2.8%
3.0%
3.2%
Revenue (m)
14,268
14,771
15,003
14,642
15,053
15,582
17,265
18,676
20,063
21,662
22,991
22,849
23,747
23,362
25,424
25,979
26,384
Operating margin
26.9%
26.9%
34.8%
37.6%
36.8%
27.7%
32.3%
31.4%
30.9%
39.1%
42.6%
43.6%
43.2%
41.4%
35.9%
29.4%
35.5%
Depreciation (m)
963
1,202
1,073
1,049
1,017
1,060
1,088
1,286
2,092
2,108
2,105
1,955
1,946
2,206
3,601
3,398
3,371
Net profit (m)
2,950
3,166
4,196
4,605
4,627
3,683
4,345
5,081
5,158
6,939
7,722
1,979
8,394
7,842
7,264
5,893
6,576
Income tax rate
26.6%
20.1%
20.1%
11.5%
13.0%
11.3%
13.3%
3.5%
7.6%
13.0%
15.7%
79.4%
12.1%
14.2%
10.7%
12.1%
12.3%
Net profit margin
20.7%
21.4%
28.0%
31.5%
30.7%
23.6%
25.2%
27.2%
25.7%
32.0%
33.6%
8.7%
35.3%
33.6%
28.6%
22.7%
24.9%
Working capital (m)
4,690
6,862
10,335
15,059
16,559
21,839
23,018
19,420
27,705
29,851
34,806
40,456
24,130
5,605
9,491
7,201
6,704
Long-term debt (m)
7,134
9,177
9,176
10,601
10,874
21,344
24,034
29,623
30,215
29,306
30,193
34,190
29,510
26,950
32,895
33,222
35,705
Equity (m)
18,964
17,869
20,386
22,667
23,944
19,029
19,060
22,096
25,778
28,083
29,875
25,241
12,500
9,673
9,409
6,700
2,419
ROIC
11.0%
11.1%
13.3%
14.3%
14.0%
9.8%
11.4%
10.4%
9.9%
12.5%
13.2%
3.2%
18.2%
19.1%
16.4%
14.2%
16.4%
Return on capital
11.9%
11.4%
14.4%
14.6%
13.6%
9.7%
11.2%
9.5%
9.6%
12.7%
13.4%
13.6%
16.5%
17.5%
14.9%
12.9%
14.8%
Return on equity
15.6%
17.7%
20.6%
20.3%
19.3%
19.4%
22.8%
23.0%
20.0%
24.7%
25.8%
7.8%
67.2%
81.1%
77.2%
88.0%
271.8%
Plowback ratio
100.0%
100.0%
100.0%
100.0%
100.0%
86.4%
74.3%
72.2%
64.1%
65.5%
61.2%
(70.0)%
58.2%
55.3%
48.3%
31.9%
37.5%
Div.&Repurch./FCF
16.7%
116.7%
39.7%
52.3%
71.2%
193.7%
85.4%
34.9%
23.9%
49.6%
62.1%
62.1%
201.8%
131.4%
73.2%
107.2%
203.6%
Capital Structure
5 Aug · 2022 | Q2
All numbers in millions
Total liabilities
$ 56,875
Total assets
$ 59,294
Long-term debt
$ 35,705
Cash and equiv.
$ 5,203
Goodwill
$ 14,865
Retained earnings
$ (28,251)
Common stock
535
Enterprise Value
$ 151,915
Working Capital
Currency: USD, in millions
2019
2020
2021
Cash & Investments
8,911
10,647
8,037
Receivables
4,057
4,525
4,895
Inventory
3,584
3,893
4,086
Other
1,888
2,308
4,319
Current assets
18,440
21,144
19,385
Acc. Payable
1,371
1,421
1,366
Debt due
2,953
91
87
Other
8,511
10,141
10,731
Current liabilities
12,835
11,653
12,184
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
2.18%
3.33%
4.71%
Cash flow
(15.25)%
(4.53)%
6.62%
Earnings
(18.87)%
72.83%
31.25%
Dividends
6.87%
4.54%
15.82%
Book value
(28.79)%
(26.15)%
(8.02)%
Insider Trading
Type
Shares
Date
Gordon Murdo
Gift
400
08/22/22
Williams R Sanders
Sale
200
08/22/22
Eckert Robert
Sale
6,600
08/18/22
Eckert Robert
Exempt
20,000
08/10/22
Eckert Robert
InKind
6,791
08/10/22
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
6,161
6,206
6,423
6,634
25,424
2021
5,901
6,526
6,706
6,846
25,979
2022
6,238
6,594
- -
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
3.11
3.08
3.45
2.76
12.40
2021
2.81
0.79
3.22
3.24
10.06
2022
2.69
2.46
- -
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
1.61
1.61
1.60
1.59
6.41
2021
1.73
1.72
1.70
1.69
6.85
2022
1.97
1.94
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Drug Manufacturers—General
CEO:
Mr. Robert Bradway
Full-time employees:
24,200
City:
Thousand Oaks
Address:
1 Amgen Center Dr
IPO:
May 1, 1987
Website:
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Recent News
· 12 Sep, 2022 · The Wall Street Journal
· 4 Aug, 2022 · The Wall Street Journal
· 1 Aug, 2022 · The Wall Street Journal
· 26 Jul, 2022 · The Wall Street Journal
· 3 Aug, 2021 · The Wall Street Journal
· 28 May, 2021 · The Wall Street Journal